ITGAV

Across TCGA pan-cancer cohorts, ITGAV RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated ITGAV data layer compared with 10 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ITGAV RNA is associated with better overall survival. In most high-consensus cancer types, elevated ITGAV expression acts as an unfavorable survival marker, although some lineages such as KIRC and COAD show a favorable association.

KIRC, MESO, and STAD are the cancer types where ITGAV RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.726	0.533	<.001	117	view →
MESO	OS	Median	All	0.434	0.658	<.001	93	view →
STAD	DFS	Median	All	0.461	0.642	<.001	73	view →
LIHC	OS	Tertile	All	0.396	0.623	<.001	54	view →
LGG	OS	Median	All	0.747	0.877	<.001	50	view →
PAAD	DFS	Quartile	All	0.170	0.445	.001	38	view →
COAD	OS	Quartile	IV	1.000	0.128	.001	35	view →
ACC	DFS	Tertile	All	0.407	0.766	.003	34	view →
UVM	DFS	Quartile	III,IV	0.251	0.900	.006	32	view →
KIRP	OS	Tertile	All	0.901	0.976	.011	29	view →
CESC	DFS	Median	All	0.393	0.678	.005	20	view →
LUAD	OS	Tertile	All	0.184	0.425	.008	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

ITGAV–KIRC (OS)

Open the KIRC breakdown →